The chief financial officer of biotech Big Pharma Amgen announced his resignation Tuesday amid the company's continuing struggles with drug development setbacks and pressure to contain the costs of its expensive drugs.
The Thousand Oaks-based company is also the target of an informal Securities and Exchange Commission inquiry into its handling of a failed Dutch study testing its drug Aranesp in patients with anemia caused by cancer. The study was stopped in December, but Amgen didn't publicly disclose its failure until February.
More
No comments:
Post a Comment